Drug updated on 5/17/2024
Dosage Form | Nebulizer (oral inhalation; 175 mcg/3mL) |
Drug Class | Anticholinergics |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD).
Latest News
![loading GIF](/img/news-loading.gif)
Summary
- Revefenacin (Yupelri) is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It is generally well-tolerated with minimal adverse events at a dose of 175 µg, making it a suitable once-daily nebulized long-acting muscarinic antagonist for moderate to severe stable COPD.
- Two studies highlight that revefenacin does not significantly increase the risk of adverse events or serious adverse events compared to placebo, with its most frequently reported side effect being worsening/exacerbation of COPD.
- Revefenacin demonstrated significant improvement in lung function, measured by mean change in trough Forced Expiratory Volume in 1 second from baseline, particularly at the dose of 175 µg/day. This improvement was found to be dose-dependent starting at 88 µg/day.
- When comparing revefenacin's efficacy and safety with other long-acting muscarinic antagonists (LAMAs) such as tiotropium and ipratropium, it might be inferior in long-term efficacy to tiotropium, while its safety profile was not deemed superior based on very low-quality evidence suggesting that further high-quality studies are needed for accurate comparison.
- Indications suggest targeted use among those suffering from moderate-to-severe respiratory impairment due to COPD. Dose-dependency hints toward opportunities for tailored treatment plans based on individual response and tolerance levels, but this aspect requires more research.
- Despite being presented as a safe and effective option, especially considering its nebulized form which may offer advantages over other LAMAs available via different administrations, there is a need for higher quality comparative studies to clarify its standing against other LAMAs regarding long-term efficacy and safety, along with comprehensive subgroup analyses and outcome studies related specifically to management strategies involving revefenacin in the effective management of COPD patients' conditions.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Yupelri (revefenacin) Prescribing Information. | 2022 | Mylan Specialty L.P., Morgantown, WV |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
Safety evaluation of revefenacin at the approved dose in patients with chronic obstructive pulmonary disease: a meta-analysis. | 2022 | Heart & Lung: The Journal of Acute and Critical Care |
The efficacy and safety of revefenacin for the treatment of chronic obstructive pulmonary disease: a systematic review. | 2021 | Frontiers in Pharmacology |